HomeInsightsStock Comparison

Alembic Pharmaceuticals Ltd vs Piramal Pharma Ltd Stock Comparison

Alembic Pharmaceuticals Ltd vs Piramal Pharma Ltd Stock Comparison

Last Updated on: Jul 16, 2025

Key Highlights

  • The Latest Trading Price of Alembic Pharmaceuticals Ltd is ₹ 1024 as of 16 Jul 15:30.
  • The P/E Ratio of Alembic Pharmaceuticals Ltd changed from 12.1 on March 2020 to 31.3 on March 2025 . This represents a CAGR of 17.16% over 6 yearsThe P/E Ratio of Piramal Pharma Ltd changed from 991.5 on March 2024 to 325.4 on March 2025 . This represents a CAGR of -42.71% over 2 years.
  • The Market Cap of Alembic Pharmaceuticals Ltd changed from ₹ 10059 crore on March 2020 to ₹ 18265 crore on March 2025 . This represents a CAGR of 10.45% over 6 yearsThe Market Cap of Piramal Pharma Ltd changed from ₹ 8165 crore on March 2023 to ₹ 29763 crore on March 2025 . This represents a CAGR of 53.90% over 3 years.
  • The revenue of Alembic Pharmaceuticals Ltd for the Mar '25 is ₹ 1783 crore as compare to the Dec '24 revenue of ₹ 1702 crore. This represent the growth of 4.77% The revenue of Piramal Pharma Ltd for the Mar '25 is ₹ 2812 crore as compare to the Dec '24 revenue of ₹ 2233 crore. This represent the growth of 25.92%.
  • The ebitda of Alembic Pharmaceuticals Ltd for the Mar '25 is ₹ 285.46 crore as compare to the Dec '24 ebitda of ₹ 270.08 crore. This represent the growth of 5.69% The ebitda of Piramal Pharma Ltd for the Mar '25 is ₹ 619.24 crore as compare to the Dec '24 ebitda of ₹ 366.92 crore. This represent the growth of 68.77%.
  • The net profit of Alembic Pharmaceuticals Ltd changed from ₹ 120.6 crore to ₹ 156.63 crore over 8 quarters. This represents a CAGR of 13.96% The net profit of Piramal Pharma Ltd changed from ₹ -98.58 crore to ₹ 153.5 crore over 8 quarters. This represents a CAGR of NaN% .
  • The Dividend Payout of Alembic Pharmaceuticals Ltd changed from 19.45 % on March 2020 to 42.97 % on March 2025 . This represents a CAGR of 14.12% over 6 yearsThe Dividend Payout of Piramal Pharma Ltd changed from 18.07 % on March 2022 to 2.68 % on March 2025 . This represents a CAGR of -37.94% over 4 years.

Share Price

* All values are in Rupees

P/E Ratio Over Time

No data available

Market Cap Over Time

No data available

* All values are in crore

Historical Share Prices

* All values are in Rupees

Revenue Over Time

No data available

* All values are in crore

EBITDA Over Time

No data available

* All values are in crore

Net Profit Over Time

No data available

* All values are in crore

Dividend Payout Over Time

No data available

* All values are in %

About Alembic Pharmaceuticals Ltd

  • Alembic Pharmaceuticals Limited manufactures and markets generic pharmaceutical products all over the world.
  • The company's state of the art research and manufacturing facilities are approved by regulatory authorities of many developed countries including the US FDA. The company is one of the leaders in branded generics in India. Alembic Pharmaceuticals Limited was incorporated on June 16, 2010 as a wholly owned subsidiary of Alembic Limited.
  • The company is engaged in pharmaceuticals business.
  • As per the Scheme of Arrangement, the 'Pharmaceutical Undertaking' of Alembic Limited got demerged and transferred to the Company with effect from April 1, 2010. In April 2011, the company ceased to be a subsidiary of Alembic Ltd consequent to the allotment of 13,35,15,914 equity shares of Rs 2 each to the shareholders of Alembic Ltd as per the scheme of arrangement.

About Piramal Pharma Ltd

  • Piramal Pharma Limited was incorporated on March 4, 2020 as a Public Limited Company and registered with the RoC. The Company offers a portfolio of differentiated products and services through end-to-end manufacturing capabilities across 17 global facilities and a global distribution network in over 100 countries.
  • It includes an integrated CDMO business, CHG business and ICH business, selling over-the-counter products in India.
  • In addition, it has a joint venture with Allergan, a leader in ophthalmology in the Indian formulations market. PPL is a leading pharmaceutical company with global operations, providing end-to-end pharma services to customers and a portfolio of differentiated pharma products across a domestic and global distribution network.
  • It operate under three business verticals - Piramal Pharma Solutions, an integrated contract development and manufacturing organization (CDMO) having a product suite in niche areas such as highly potent Active pharmaceutical ingredients (APIs), Finished dosage forms (FDFs), antibody drug conjugates, potent sterile injectable, hormonal oral solid dosage forms, biologics and vaccines; Piramal Critical Care, a complex hospital generics (CHG) business in the areas of inhalation anaesthesia, injectable anaesthesia and pain management, intrathecal therapy and other injectable; and India consumer healthcare (ICH) business, selling well-known OTC brands.

Alembic Pharmaceuticals Ltd News Hub

News

Alembic Pharma appoints G. Krishnan as new CFO

Krishnan is a seasoned finance professional with over 22 years of experience across the ph...

Read more

07 Jul 2025 14:58

News

Alembic Pharmaceuticals announces acquisition of Utility Therapeutics

Alembic Pharmaceuticals Inc., wholly owned subsidiary of Alembic Pharmaceuticals has acqui...

Read more

03 Jul 2025 09:15

News

Alembic Pharma inks deal to acquire Utility Therapeutics for $12 million

Utility Therapeutics is involved in the development and approval of two brand pharmaceutic...

Read more

03 Jul 2025 10:40

News

Alembic Pharma jumps after receiving USFDA nod for Doxorubicin Hydrochloride Injection

The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD)...

Read more

30 Jun 2025 10:12

News

Alembic Pharmaceuticals Ltd leads gainers in 'A' group

Jindal Worldwide Ltd, RattanIndia Power Ltd, AAVAS Financiers Ltd and Force Motors Ltd are...

Read more

30 Jun 2025 12:00

News

Volumes soar at Alembic Pharmaceuticals Ltd counter

Jyoti CNC Automation Ltd, Raymond Ltd, TBO Tek Ltd, Raymond Lifestyle Ltd are among the ot...

Read more

30 Jun 2025 14:30

Piramal Pharma Ltd News Hub

News

Piramal Pharma to conduct AGM

Piramal Pharma announced that the 5th Annual General Meeting(AGM) of the company will be h...

Read more

14 Jun 2025 14:54

News

Piramal Pharma's Aurora unit completes USFDA inspection

Piramal Pharma announced that the US FDA conducted a general GMP (Good Manufacturing Pract...

Read more

02 Jun 2025 16:21

News

Piramal Pharma's Canada facility gets zero USFDA observation

According to a regulatory filing, the inspection was carried out from 26 May 2025 to 30 Ma...

Read more

02 Jun 2025 11:16

News

Piramal Pharma allots 35 lakh equity shares under ESOP

Piramal Pharma has allotted 35 lakh equity shares under ESOP on 21 May 2025. Consequent to...

Read more

21 May 2025 15:37

News

Board of Piramal Pharma recommends final dividend

Piramal Pharma announced that the Board of Directors of the Company at its meeting held on...

Read more

15 May 2025 10:18

News

Piramal Pharma's Turbhe facility successfully completes USFDA inspection

Piramal Pharma announced that the USFDA has issued an Establishment Inspection Report (EIR...

Read more

12 May 2025 12:47

SWOT Analysis Of Piramal Pharma Ltd

Strength

3

S

Weakness

1

W

Opportunity

0

O

Threats

1

T

SWOT Analysis Of Alembic Pharmaceuticals Ltd

Strength

1

S

Weakness

2

W

Opportunity

0

O

Threats

1

T

BlinkX Score for Piramal Pharma Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

BlinkX Score for Alembic Pharmaceuticals Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

FAQs for the comparison of Alembic Pharmaceuticals Ltd and Piramal Pharma Ltd

Which company has a larger market capitalization, Alembic Pharmaceuticals Ltd or Piramal Pharma Ltd?

Market cap of Alembic Pharmaceuticals Ltd is 20,130 Cr while Market cap of Piramal Pharma Ltd is 28,538 Cr

What are the key factors driving the stock performance of Alembic Pharmaceuticals Ltd and Piramal Pharma Ltd?

The stock performance of Alembic Pharmaceuticals Ltd and Piramal Pharma Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Alembic Pharmaceuticals Ltd and Piramal Pharma Ltd?

As of July 16, 2025, the Alembic Pharmaceuticals Ltd stock price is INR ₹1024.1. On the other hand, Piramal Pharma Ltd stock price is INR ₹214.7.

How do dividend payouts of Alembic Pharmaceuticals Ltd and Piramal Pharma Ltd compare?

To compare the dividend payouts of Alembic Pharmaceuticals Ltd and Piramal Pharma Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.
Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.
up arrow
Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions

Join the

Future of Trading

with BlinkX

#ItsATraderThing

Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions